decemb anoth quiet period eu space cover compani
term result unsurprisingli given holiday break clinic regulatori
newsflow continu expect progress period
progress clinic develop remov near-term fund overhang
clinic standpoint also posit updat biomup lead asset
hemoblast approv fda earlier expect whilst mereo saw posit
albeit noisi top line phase result aecopd drug expect clinic
newsflow hansa mereo shield vectura like
meaning impact valuat name
north american colleagu note first gene therapi approv
us spark therapeut luxturna approv rare eye diseas biallel
retin dystrophi posit
implic space teva cost
cut/restructur program reflect continu question uncertainti
gener space continu updat cvs-aetna deal creat behemoth
vertic integr care deliveri us larg cap pharma compani
report miss phase trial notabl celgen newli diagnos
follicular lymphoma biogen/eisai alzheim diseas
takeaway find document
takeaway month page
eu research valuat tabl page
month ahead trade idea page
versu consensu upcom result
newsflow us page
eu investor need know page
takeaway month eu healthcar research
decemb quiet month term result consort medic report posit
interim result whilst major newsflow coverag evolv
around regulatori clinic updat hansa medic rais
share place progress clinic develop kt follow-on indic
think remov near-term fund risk overhang stock
see hansa fulli fund go confid valu hansa
igg-cleav technolog lead indic kt acut auto-immun
condit biomup report fda approv asset hemoblast well ahead
expect indivior saw asset approv admittedli
end-nov mereo report posit albeit noisi top line phase result aecopd
elsewher move vectura sector perform under-perform basi
consensu estim come downsid risk sentiment valuat
lessen although still see risk suffici catalyst
horizon
highlight eu healthcar research
hansa medic swedish clinic stage biotech compani focu novel
immunomodulatori enzym use transplant acut autoimmun diseas
rais sek around mcap issu share price
sek fund continu develop exist portfolio rais
remov near-term fund risk overhang invest case see
compani fulli fund take lead asset approv process
transplant lead asset continu explor follow-on indic
initi link highlight fund risk invest
reason hansa would need reach break-even suggest shortfal
exist howev see merit manag strategi rais smaller amount
ahead upcom event highd studi read-out potenti bla
submiss equat materi re-rat share price allow
futur fund rais improv term proce allow hansa captur
data follow-on indic heart lung liver transplant anti-
gbm acut myasthenia gravi addit acut autoimmun condit well
oncolog use re-set patient immun system prior therapi alreadi
adjust forecast reflect propos increas share count
associ balanc sheet cash flow chang sotp valuat move sek
sek approach key inflect point confid hansa igg-cleav
technolog yield valu beyond initi kt indic look updat
data point highd investigator-l studi ii regulatori progress within
kt indic iii next develop step timelin data point new
indic follow rais
biomup hemoblast approv ahead schedul
biomup receiv fda market approv hemoblast bellow flagship
product sever month ahead schedul guid ipo around
three month ahead expect approv decis allow
biomup market hemoblast us bleed control surgic procedur
heart surgeri gener surgeri orthopaed surgeri etc come back
believ strong clinic data patient studi efficaci minut
versu control arm hemoblast work quick effect
market lead product requir prepar time
view approv clear posit recruit process sale
market staff full swing see first revenu come slightli earlier
estim await updat commercialis hemoblast
next expect hear biomup result expect
hansa medic rais roughli mcap price
small discount prevail price issu share proce
use fund continu develop compani exist portfolio
offer subject sharehold approv egm expect
around decemb forecast movement reflect propos increas share
count associ balanc sheet cash flow chang account cash
sotp valuat tick slightli move closer key inflect point see
rais help remov key overhang risk confid hansa igg
cleav enzym technolog deriv valu simpli kt indic
indv quick thought approv
indivior announc fda approv first in-class monthli inject
buprenorphin formul treat moder sever opioid use disord
materi posit compani see share potenti rise
today model valu sublocad per share given asset
launch expect caution gener risk film franchis
resolv sublocad revenu start ramp
posit phase iv data tudorza help rejuven sale
circassia partner astrazeneca announc posit top-lin result ascent
phase iv post-market studi tudorza long act muscarin antagonist
patient moder sever chronic obstruct pulmonari diseas copd
document cardiovascular risk factor ascent studi met primari efficaci
endpoint tudorza demonstr statist signific reduct rate
moder sever copd exacerb compar placebo also demonstr
favour cardiovascular safeti profil time patient experienc first
major advers cardiovascular event similar placebo cardiovascular diseas
common comorbid copd spoken circassia manag
bullish data hope add multipl part result
csrt tax rate optic impact track catalyst horizon
consort interim result broadli in-lin expect aesica
turnaround progress revenu margin albeit bespak growth slow
pipelin event occur ep impact tax time differ may
distract investor attent go detail see posit underli
momentum put small forecast upgrad possibl
upcom pipelin catalyst pipelin partner anticip
outcom gener advair program june syrina biolog asset
remain track albeit time updat provid nudg ep
improv outlook aesica sotp valuat move
reiter outperform rate whilst growth overal appear low ep
normalis tax rate think sustain long term
increas pipelin asset launch syrina particular
ep think share remain cheap qualiti busi ii
option valu pipelin
mereo releas posit albeit noisi phase top-lin result clean safeti
profil map kinas inhibitor use treatment acut
exacerb copd importantli bct hit exploratori endpoint reduc re-
hospitalis rate bode well phase saw asset
highest risk within mereo pipelin see valu rise per share
find commerci partner speak manag understand
next step review full data set potenti present data upcom
scientif confer begin partner discuss would imagin hear
partner discuss manag
mph busi updat highlight multipl upcom clinic event cash better
expect
mereo busi updat mereo busi updat highlight key upcom data
point pipelin bct full data potenti partner
studi start hope data recent in-licens azd
asset indic busi period compani one mix point
key orphan asset bp eu timelin may move six month right
suspect could harmonis eu us regulatori demand
henc minimis clinic trial expens potenti help target earlier review us
perhap chang overal view key data point set unlock
valu mereo prudent deploy capit asset demonstr cash
better expect model suggest compani still valu
orphan asset bp suggest good option valu investor
move sector perform downsid lessen
move sector perform under-perform basi consensu estim
come realist level downsid risk sentiment valuat
lessen whilst vectura like pleas say goodby think
time turn posit given risk also see suffici
catalyst horizon forecast chang account buy-back
expect complet full otherwis make chang underli
estim consensu expect come consider year
still consensu ebitda still see risk
delay probabl launch date howev
think buy-sid expect also move perhap even ahead sell-sid
expect mani written altogeth
bup hemoblast us approv ahead schedul
biomup receiv fda market approv hemoblast bellow flagship
product sever month ahead schedul guid ipo around three
month ahead expect suspect approv could come
sooner compani highlight success fda inspect facil ahead
usual timelin would expect pre-market approv pma submiss
approv allow immedi sale hemoblast us whilst compani
still activ recruit sale market team us still see first revenu
come slightli earlier estim news clear posit
compani remov arguabl greatest near term risk invest case
healthcar valuat tabl sector perform chart
denot act broker
capit market estim factset price inform base price market close bst decemb
companyrecupsideptpricemcapevforecast growthforecast growthforecast compound-annual-growth-rate compound-annual-growth-rate compound-annual-growth-rate spec spec medic aboutperform spec seknanananananananananananahorizon discoverysector perform spec biopharma outperform spec therapeuticsoutperform spec exclud shield salesev ebitdap eu healthcar
exhibit weight averag share price perform coverag versu ftse share
jan dec
jan dec
jan dec
jan dec
jan dec
jan dec
share exhibit coverag perform versu peer wider sector
jan dec
jan dec
jan dec
medicalnmc eco anim groupindiviordechra pharmaceuticalscv groupudg careabcamgenusclinigen groupcaretech holdingsi pharmaconsort medicalhorizon discoveri groupfts sharestoxx europ eastrazenecasmith nephewcambian groupbtgglaxosmithklinevectura groupshiresinclair pharmaspir care gp hikma pharmaceuticalsbenchmark holdingscircassia medicalnmc indivioreco anim groupdechra pharmaceuticalscaretech holdingshorizon discoveri groupgenusabcami pharmaclinigen groupudg carecambian groupcv groupfts sharebtgastrazenecastoxx europ esmith nephewconsort medicalglaxosmithklineshirespir care gp vectura groupsinclair pharmabenchmark holdingshikma pharmacuretiscircassia medicalnmc horizon discoveri groupcambian groupdechra pharmaceuticalsclinigen groupianc pharmagenuscaretech holdingsindiviorabcambtgudg caremereo biopharma groupeco anim groupastrazenecaconsort medicalcircassia pharm ftse sharestoxx europ esmith nephewcv groupvectura groupconvatec groupglaxosmithklineshiresinclair pharmaspir care gp benchmark holdingsshield therapeuticscuretishikma pharmavernali month ahead trade idea
look januari interim trade updat abcam dechra
clinigen trade updat horizon discoveri sinclair pharma vectura
well list clinic data regulatori decis investor keep
radar come month expect hear hansa medic full
enrol highd studi mereo new-year cureti
go/no-go approv decis unyvero system
interim trade updat look perform key product line
rabmab etc updat companion diagnost space improv
oper margin see rabmab revenu driven strong underli growth
growth rate forecast primari antibodi sale driven solid singl digit
underli growth fcst revenu ebitda ep forecast
respect
fan abcam move sector perform outperform
trade updat juli given re-rat occur yet hear
much new target market updat companion diagnost etc continu
believ re-rat unlik without posit updat new market
interim trade updat think investor interest focus upon two
recent acquisit quantum pharma immc underli growth unlicens
medicin ga/ma specif roll on-line platform cliniport
recent note link perform deep dive clinigen evolv unlicens
medicin strategi on-line platform cliniport eu hospit pharmaci
survey link recent acquisit manag continu
deliv switch project ga contract whilst build nich portfolio
product put on-line platform see re-rat
revenu gross profit ebitda ep forecast
respect per divis expect gross profit clinic trial servic
commerci medicin unlicens medicin
revenu ebitda ep forecast
respect division level revenu estim eu pharmaceut
north america respect
dechra see long-term growth opportun increas spend per pet
increas number pet key territori ii expans new territori iii
pipelin launch howev would also need see whether custom de-
stock us alongsid hurrican relat issu lacklustr eu market
neg impact statement peer virbac led potenti
disrupt dechra perform link sparc
revenu ebitda ep forecast
respect per divis estim revenu product servic dharmacon
come respect
believ investor focus upon dharmacon acquisit integr
ii underli revenu growth iii profit whilst full year guidanc
reiter interim meant signific step led us lower
forecast accordingli octob see risk horizon meet
target alongsid think updat
biotechnolog busi particular could seen neg investor
revenu ebitda ep forecast respect
product level forecast silhouett revenu ellan revenu
perfectha sculptra deliv respect
whilst number physician us train use silhouett continu progress
well issu partner almiral core non-aesthet busi front mind
alongsid updat us look progress ex-u busi key
reach break-even underli revenu growth product given weak
investor sentiment today think updat posit could
materi improv post trade updat januari
revenu ebitda ep forecast
recent move vectura sector perform under-perform basi
consensu come realist level downsid risk sentiment
valuat lessen yet posit stock risk
fda disput resolut process see suffici catalyst
horizon advis patienc
exhibit potenti catalyst timet coverag coverag peer
compani inform factset estim note indic project result releas date
stockjanuaryfebruarychabcam interim trade updat mid-jan thermo fisher result feb result feb horizon discoveri capit ket day feb biorad result feb result merck kgaa result result jan baxter result jan result feb integra lifesci result feb result feb medic solut result ergom result result jan result feb preliminari result tbc clinigeninterim trade updat tbc interim result tbc cumberland result result jan lonza result jan result feb gerresheim feb recipharm resutl feb coloplast result feb result feb smith nephew result feb result feb becton dickinson tbc medtron result feb advanc medic solut result lilli result jan interim trade updat mid januaryzoeti result feb interim result feb result ch vetoquinol ch medicalful recruit highd studi potenti feedback fda meet track statusargenx result ch discoveri trade updat mid-januarythermo fisher result feb result feb capit ket day feb biorad result feb kgaa result pdufa date jan orexo result jan result usual feb camuru result feb titan result tbc result tbc mereo biopharmashield vifor pharma result ch trade updat earli januaryallergan result feb almiral feb preliminari result tbc vectura pre-clos trade updat jan result feb pacira result feb disput resolut fda gener advair potenti re-submiss timelin preliminari resultsclear decis fda unyvero devic result tbc qiagen result jan diasorin result biomerieux result line data aegis-ckd trial feraccru novel oral iron tablet patient chronic kidney diseas iron defici anaemia top line result oral aromatas inhibitor develop obes men hypogonad hypogonad
versu consensu upcom result
exhibit versu consensu compani report soon note consensu expect may small number contributor
factset capit market estim note highlight limit consensu data
stockmetricconsensu fcst fcst fcst june year june year profit june year vecturaclinigenconvatechorizon discoverysinclair pharmacureti newsflow item north america
first gene therapi us
rel quiet period read across point us whole point
believ highlight teva aggress cost cut program amidst on-go
uncertainti gener sector approv spark therapeut luxturna
make first approv gene therapi us cvs-aetna deal creat
behemoth vertic integr consum centric value-bas care
continu question
uncertainti gener
cvs-aet merger creat
giant vertic integr
find next blockbust
continu condit
difficult tackl
matthew eckler report fda approv spark therapeut luxturna gene
therapi treatment mutat associ retin dystrophi broad
label make luxturna first gene therapi approv us detail
price launch strategi follow januari matthew current model estim
sale consensu reflect temper initi uptak
view need specif around reimburs physician
randal stanicki believ teva cost cut cog sg
aggress right move overal leav question revenu outlook
reiter continu uncertainti around gener market us teva also
pursu optimis us gener busi basic discontinu product
get price look pursu price adjust select product
georg hill provid thought much reported-on acquisit aetna
per share slightli rang report late last week aet
sharehold receiv cash share sharehold
combin compani issu new debt deal
expect meaning impact earn near term low mid-singl digit
accret year two identifi near term synergi georg
write merg cvs/aetna creat behemoth healthcar servic space
combin revenu ebitda rival
deal expect close investor like focu
regulatori process approv busi integr potenti divestitur
custom loss georg view deal offens aetna look
creat vertic integr consum direct deliveri futur oppos
respons threat amazon
newly-diagnos follicular
brian abraham saw sever larg cap compani report miss phase
trial celgen announc announc relev trial evalu
revlimid rituxan treatment mainten vs standard care chemotherapi
lymphoma achiev
superior either primari endpoint complet respons rate week
biogen partner eisai announc beta-amyloid antibodi use
alzheim diseas meet success criteria month endpoint
continu studi brian note alongsid eli lilli failur
sola merck bace inhibitor failur biogen/eisai struggl highlight
inher challeng produc clinic meaning benefit alzheim beta-
exhibit stock cover dougla miehm
titl link note
shpg appoint andrea busch head
research chief scientif offic
 fda request addit data
shire shpg announc andrea busch phd join compani execut vice presid head
 chief scientif offic begin januari current interim head howard mayer md becom
compani new chief medic offic also effect dr busch current head drug discoveri bayer
pharmaceut divis year tenur compani held increasingli senior role prior
current role dr busch global head cardiovascular research hoechst sanofi-aventi
morn announc fda request addit data fulfil previou addit inform
request compani submiss extend claim steril includ termin steril
duodenoscop note compani receiv initi correspond late septemb provid
addit data agenc novemb ahead timelin submit follow-up end
novemb compani indic morn releas next written exchang fda schedul
year-end anoth discuss schedul earli manag note final label could
submit time
vrx receiv fda approv lumifi
lumifi get fda nod yesterday valeant announc receiv fda approv lumifi first over-the-counter eye drop
develop low-dos brimonidin tartrat treatment ocular red approv come ahead
decemb pdufa date lumifi made avail purchas retail
exhibit stock cover matthew eckler
titl link note
consist prior datacut
updat result phase ii anti-diarrh prophylaxi control studi consist sabc abstract avoid worsen
diarrhea main-focu colestipol arm
live continu show good
safeti potenti use combin
updat phase data reinforc safeti profil earli sign efficaci preclin result suggest
synergi cytarabin continu show promis aml good safeti combin suggest potenti
explor front-lin poster weekend present updat clinic pre-clin result
hem quick take variabl level
fviii express expect
given still small patient number data rais question answer variabl fviii level kinet
expect
look like show-m
stori increasingli competit hem race
updat result rais question around variabl fviii level abil gener dose respons
acknowledg work need done understand kinet dose today sell-off appear
overdon consid onc broader pipelin said anticip hemophilia shift show stori
investor pend updat data next year
live next development
candid unveil ind
plenari session today introduc inhibitor develop scd ind-en studi start
neratinib get day eu drug court
ema schedul sag review neratinib assum addit questions/clock stop chmp opinion
appear track
approv broad label
approv first gene therapi us come earli broad label price tba januari expect luxturna
get thumb fda morn fda approv luxturna voretigen neparvovec ahead januari
pdufa date approv luxturna gener expect price share follow unanim
posit fda advisori panel octob
exhibit stock cover randal stanicki
titl link note
 ema review esmya liver injuri
thought
releas date dec european medicin agenc ema indic start review esmya
uterin fibroid follow four report seriou liver injuri patient treat medicin esmya
current sold eu canada file approv us nda accept oct
unclear impact approval/outlook come amidst could approv
import drug think could billion peak potenti million risk
adjust refer one six star
nucynta announc
restructur cc et
market depo announc sign definit commerci agreement nucynta
ir xr expect close earli januari follow hsr clearanc would give product
exchang royalti rate total revenu upon close pay up-front licens fee cash
payment equal depo cost inventori greater twelv month date time close
nucynta deal smart pivot focu
shift creativ busi develop
coll/depo host call discuss nucynta transact restructur plan depo provid
guidanc expect feb call deal boost ebitda ii provid opportun pivot away
opioids/pain perhap under-appreci iii may provid long-term life-cycle strategi focu shift
need busi develop execut platform better posit rais target
simplifi simplifi tax propos
reform move forward
formal negoti set begin soon reconcil hous senat version tax cut job act
landmark tax reform bill reform look like visibl improv dug deeper bill spoke
tax expert better understand potenti impact specialti pharmaceut coverag addit
address overal odd success highlight key provis perspect
multi-national corpor ii lever compani iii specialti brand compani none mutual
teva bloomberg headlin cost cut
consist buysid expect
continu see downsid risk
bloomberg report teva plan cut job lower expens billion billion
littl less half report also indic compani plan proceed
equiti offer near term bottom line line buysid expect
surpris
ahead formal restructur announc
look five import question
follow friday bloomberg report disclos restructur detail ahead formal announc taken
look five question matter stock overal near-term volatil remain fundament
pressur thu far teva follow predict game plan asset sale cost restructur addit strateg
lever less clear maintain under-perform
teva announc cost cut bigger
expect sever question cc
teva announc formal cost restructur morn follow confer call morn
et teva point reduct cost base billion end cost base billion
cut employe base
titl link note
teva takeaway restructur call
gener strategi broader competit
teva call discuss restructur plan end stock back deeper-than-expect
cost cut guidanc provid call come late feb primari investor focu go around
impli ebitda run-rat also expect teva gener strategi get focu like broader
competit implic deeper cost cut clearli posit step add ebitda support reflect
model enough chang view under-perform rate
aggress cost cut expect
revenu uncertainti challeng
bull/bear debat pick dramat bull camp point newfound cost-driven ebitda support path
de-lev bear camp focus revenu risk uncertainti around gener strategi latter
camp recogn new ceo kare schultz deliv strong messag today cost cut nevertheless road
recoveri remain long still unansw question remain under-perform rate
 symphoni exparel data
anoth move right direct
market close symphoni report institut sale data million exparel
impli increas year-over-year rel last month data link
continu see path market post
view new timelin
agrx announc receipt twirla nda resubmiss discuss path forward detail
discuss manag around implic path forward push approv launch earli
remain risk adjust potenti much quicker approv exist lower price target
reflect delay remain optimist approv
exhibit stock cover glenn novarro brandon henri
titl link note
thv outlook topic interest
note road takeaway non-
deal road show
ew share recoup loss suffer follow disappoint expect guidanc bracket
consensu expect manag reiter guidanc equal interest manag commentari
mitral tricuspid pipelin key clinic updat given recent run-up share prefer add
pull-back
senhanc launch gain traction europ compani recent announc receiv order
deliv system asia compani sold senhanc hospit taiwan howev compani
book sale system receiv approv compani sold first unit
ahead expect typic take quarter sell robot recal compani receiv approv
senhanc octob
last week attend radiolog societi north america rsna annual confer chanc
meet manag team variou radiolog breast health manufactur
initi coverag outperform
ew guidanc line forecast
initi coverag outperform rate price target expect
take market share ambulatori cardiac monitor market given zio servic product believ superior
competitor forecast revenu growth next two year driven market expans increas sale
forc product favour reimburs polici
ew forecast ww revenu rang consist estim guidanc pleas
see report discuss impli growth ew forecast ep rang
predict rang rbce consensu
entl logic step increas
presenc ent space
paid reason price entl compani look acquir prior compani ipo januari
acquisit nearli doubl sale forc ent market give presenc
thesi intact post investor day buyer
pullback
manag provid sale ep guidanc line expect although ww tavr guidanc look
conserv us ew investor day alter long-term invest thesi continu view ew best
growth stori large-cap med-tech given move share price month buyer
held investor day last week manag re-affirmed guidanc provid look
plan target includ revenu adjust ebitda organ growth
upsid codman provid acceler ou growth execut new product launch
codman deal key stock perform go forward
titl link note
mmmbop bryan hanson hire
bryan hanson hire new presid ceo posit share view bryan hanson except
strong hire given year medic devic experi recent medtronic/covidien street
know mr hanson well believ right person lead on-going turnaround effort mr hanson
previous serv member mdt execut committe evp group presid minim
therapi group revenu gener busi prior januari acquisit covidien
mr hanson serv group presid covidien global respons covidien busi segment
name posit ad medic suppli emerg market develop market
respons also previous serv group presid medic devic covidien well group
presid surgic solut presid energy-bas devic
exhibit stock cover frank morgan
titl link note
continu progress face
follow-up first glanc note date provid addit commentari updat estim
merger creat healthcar giant aet plan merger make long-term sens strateg perspect strong cash flow management
expect de-lever rapidli rais pt aet maintain outperform given spread
current price price impli cash stock merger agreement
up target medicar advantag
growth open enrol end soon
increas growth outlook individu group medicar advantag help give investor
confid outlook
divest dmg back pure play
expect found buyer primari care unit davita medic group dmg acquir
nyse optum health servic subsidiari all-cash transact expect
close
thursday close announc board director approv increas
share repurchas author bring total author
tax reform offer mix impact
hospit coverag depend leverag
add dec
show strongest growth
influenza-lik ill climb
patient visit week
morn humana inc nyse sp announc approv share repurchas author expir
program replac previou author exhaust recal
complet previous announc acceler share repurchas asr sinc complet
remain amount previou author
tax reform legisl move closer fruition updat thought financi impact hospit
coverag univers specif annual ep impact current estim updat
actual estim legisl pass law howev provid analysi give rel
context specif provis could offer put take focus two issu
believ largest impact
releas medicar advantag part enrol data decemb ad member
roll sinc novemb bring total enrol membership country-wid increas sinc
decemb last year medicar part enrol uptick sequenti increas sinc decemb
instanc influenza-lik ill increas patient visit week flu season decemb
exceed nation baselin chart follow page illustr accord cdc weekli
 influenza surveil report nationwid week end decemb week flu season
patient visit due influenza-lik ill ili exceed nation baselin level seven
cdc ten hh surveil region report elev level ili activ three report normal ili level
potenti deal pe firm
wall street journal report weekend knd advanc talk acquir humana inc nyse
sp along welsh carson tpg approxim per share none parti confirm
report
titl link note
confirm strateg valu
news nashvil
weekli perspect healthcar
industri compani news valuat
propos updat medicar
announc demonstr valu healthcar provid advanc integr care deliveri
strategi news may reduc likelihood provid acquir would
surpris see deal eventu emerg depend attract provid geograph coverag
rais price target believ manag obtain maximum valu
highlight week end decemb sector price perform week end decemb healthcar
servic stock outperform broader market health servic select index spsihp grew
versu uptick strongest-perform subsector ambulatori surgeri
gain acut hospit gain versu gain prior week manag gain
averag vs declin prior week healthcar reit weakest-perform subsector last week
new model would phase impact individu mco difficult estim wednesday
releas part advanc notic medicar advantag payment propos updat part risk
adjust model specif requir centuri cure act propos new risk adjust model
includ addit mental health substanc use disord chronic kidney diseas condit
exhibit stock cover brian abraham
titl link note
mru bispecif continu progress clinic key decis point solid tumor beyond breast cancer
expect soon ph data could provid insight potenti novel aml target like sometim first
part next year ev strong underli platform progress earli pipelin continu
believ share under-valued
highlight top-read differenti piec novemb provid updat view feedback
data preview celg ipr concern sentiment link note found appendix
track weekli script data key biotech product market coverag univers begin week
quarter note im sale project week trend may limit due shorten thanksgiv holiday week
overal script two week notabl otezla w-o-w qtd ocaliva w-o-w
qtd trend discuss
futur commerci pipelin prospect
yesterday capit market biogen pipelin neuro kol day host seri physician-scientist expert
across sever highest interest area neurolog also sat biogen sma lead latest develop
spinraza takeaway provid within adjust target
screen found pivot studi anti-bcma car-t partner becom avail today
link trial time expect though believ progress registration-en ph ii studi
highlight promis program gain increas street attent yet help drive celg share
follow recent declin someth believ updat ph ib data present may help turn around celg
spent time road sr management continu believ hcv royalti place strong floor
valuat select fxr agonist underappreci notabl meet potenti
clinic readout rsv announc hbv candid select draw new attent broader pipelin
drive add share upsid
ftc document suggest may acquir privately-held cell design lab car-t technolog compani though
yet confirm believ potenti acquisit though transform would dovetail well
state goal bd around enhanc safeti applic cellular therapi sinc kite acquisit
affirm long-term invest cellular therapi next-wav foundat oncolog
outstand ph ii mdd data show differenti profil could game-chang replic ph iii
lead out-yr sale -- addit de-risk oral pipelin across multipl neuro indic rais target
despit today move still see consider fundament upsid opportun good likelihood takeout
premium current level
bcma drive valu celg
catalyst rich hbv rsv program
data stand alon -- may
titl link note
new patent could improv ip
po celg set sight
upcom markman hear grevlimid
line report yesterday cite ftc document found suggest us like acquir privat car-t
technolog compani cell design lab cdl formal announc acquisit believ price
deal disclos up-front mileston reason given potenti
applic technolog kite platform today pr also note preclin program mm well solid
tumor prostat cancer hepatocellular carcinoma remain posit share
spotlight today certainli robust ph ii mdd result risk stori question
commonli receiv investor surround limit patent protect brexanolon note two patent applic
publish today grant could provid robust protect gener potenti neurosteroid
dr reddi ipr deadlin pass see high hurdl gener succeed argu invalid celg
polymorph patent believ succeed non-infring imper drl leverag
settlement view celg argument stronger lt thing take time play note upcom
markman hear brief due soon hear potenti could provid key first clue potenti victor --
believ swing celg favor
new updat data imdz key oncolog asset present today show strong evid activ
nhl -- potenti large-mkt oppti set add anoth shot goal view significantli under-valued
underappreci stori reiter outperform
look toward life revlimid
solid tumor strategi take
much-need uniqu approach
theme weekend relat cover compani includ high enthusiasm long-
term promis durabl cellular therapi off-set somewhat concern complex administr
reimburs reassur durabl late-stag car-t gild/kit celg/blu interest new data
underappreci asset small-cap imdz progress foray hematolog
attend last night celg investor event abundantli clear manag
focus ever plan life revlimid necessarili dramat announc
event would significantli chang sentiment believ present highlight celg abil
doubl winner emerg broad partner pipelin capac leverag intern
extern asset differenti even crowd space interest/willing invest heavili posit
step toward improv percept diversif revenu sustain drive appreci share
host dinner sunday even lymphoma kol top academ center overal relat
cover compani physician echo mani concern heard throughout weekend
complex deliv get reimburs car-t therapi commerci set continu believ
make initi uptak cellular therapi like gild yescarta gradual believ issu
insurmount continu see signific lt opportun field
survey psychiatrist gaug reaction recent ph ii data view potenti impact mdd
treatment paradigm result indic doc view profil significantli differenti expect role
treatment-resist naiv pt could translat much larger lt revenu opportun even
estim contempl result replic ph iii continu see share under-valued
titl link note
battl among three car-t therapi nhl gild/kit juno/celg nvs/upenn took center
stage morn far earli call winner vs loser bottom line look highli effect
reason durabl subtl differ potenc persist safeti manufactur among
clearli remain earli inning understand optim improv benefit/risk valu car-
thesi remain like grow pain high lt revenu opportun cell therapi evolv
foundat lt diversif
morn announc agreement co-develop commerci crsp sickl cell diseas
beta-thalassemia -- first six treatment research collabor cf remain core focu
valu driver believ expans gene edit help improv investor confid abil
diversifi around cf long-term remain posit share
regulatori feedback type
open new door glpg opt filg
eu lock-up/standstil set close
takeaway manag dinner
partner guidanc call today provid sever posit updat baricitinib time plan addit
indic suggest safeti analys regulatori discuss favor epacadostat ph iii
melanoma data remain key focu binari event high enough convict get front though
posit progress bari help improv potenti valuat floor reward/risk
even market close avx announc start type trial see major surpris
believ design type studi appropri assess potenti intrathec administr work
across variou age group -- though whether replic iv strong benefit type patient unknown overal
believ share fairli balanc good likelihood earli approv type solid mechanist rational
unknown type larger sma market overal complex market dynam
even glpg announc new develop filgotnib partnership opting-in eu commerci
effort spell in-lin financi term formal disclos close lock-up standstil
opportun catch glpg enthusiast opportun add commerci capabl remain
highli encourag partnership believ filgotinib shown potenti best-in-class properti larg
market acknowledg lock-up expiri could fuel potenti takeout discuss though inflamm space
becom crowd much glpg valuat predic potenti see reward/risk fairli balanc
current share price
host ceo cfo cso ny particularli struck confid novelti
approach toward depress acut treatabl illnessa paradigm-shift concept believ could potenti
hasten regulatori path enabl game-chang commerci opportun street current
contempl despit recent upsid still see meaning addit appreci share
track weekli script data key biotech product market coverag begin week
quarter note im sale project week wk qtr script pull back last week post-
thanksgiv bounc perhap limit w-o-w interpret though track rx point qtd notabl otezla w-o-
 qtd ocaliva w-o-w qtd
biweekli review interest literatur
scienc edit
lit bit biweekli scientif literatur digest highlight recent journal articl believ could impact
coverag univers and/or broader biotech landscap edit approxim cover first half dec
titl link note
look back get today surfac seem pretti solid year
biotech sector ibb nbi indic ytd edg
polit rhetor concern drug price polici initi cool substanti sinc time last year
open door broader money flow sector innov new car-t gene therapi cystic fibrosi
old depress headach area abound scott gottlieb helm fda maintain
permiss pragmat predict approach
publish stand-alone result survey includ sever addit analys compar generalist vs
large-cap continu sputter
mru court appeal reaffirm
spent time road manag team compani reiter enthusiasm lead drug
selinexor laid method path increas chanc bring market believ follow
enter catalyst-heavi remain underappreci stori could garner attent year
sever card turn selinexor begin april continu highlight promis profil
partner eisai report ph ii studi beta-amyloid antibodi alzheim meet success
criteria endpoint though continu alongsid sola failur recent bace
inhibitor failur believ continu illustr inher challeng produc clinic statist
meaning benefit ad beta-amyloid orient therapi like adu -- critic lt valu driver -- though
certainli preclud possibl adu could ultim succeed less potent protofibril-target mechan
likelihood modest benefit observ sinc stop futil thought benefit/risk
reason data given low buy-sid expect though adu ph iii readout like yr away
ms/sma unlik surpris could make setup bit less interest
even celg report relev trial revlimid rituxan prove superior r-chop first-lin
follicular lymphoma view increment disappoint though believ lymphoma trial becom less
driver investor focu diversif beyond revlimid still remain rational nhl
studi could succeed optic would nice anoth win follow data especi come
still see share consider under-valued higher-po catalyst would use weak
earlier today mru announc feder circuit deni regn request reexamin inequit
conduct claim uenforc patent mark third consecut rile mru favor
expect follow rule protect mruss transgen mous common light chain antibodi
technolog europ japan affirm strong ip posit biclon platform continu believ
share under-valued base progress earli pipelin strong underli antibodi platform
morn announc initi ph iii oca studi nash cirrhot slip prior
guidanc believ mostli expect given time year fact studi yet start base
discuss manag morn believ reflect major chang fda overal
view drug continu expect label updat help reduc overhang set stage add pbc growth
see under-valued lt opportun nash
exhibit stock cover kennen mackay
titl link note
repatha label expand includ
cv benefit see immedi
inflect unlik
pnh updat narrow market
look viabl decreas pt
faster anticip launch
competit pressur eloct
today announc repatha label updat includ data risk reduct heart attack stroke
coronari revascular potenti improv market reimburs dynam commerci traction
seen repatha label publish yet though anticip updat label includ repatha
reduct risk heart attack reduct risk stroke reduct risk coronari revascular
repatha label previous includ phrase effect repatha cardiovascular morbid mortal
publish inclus result approv label evalu fda anticip could
amend reflect specif improv cv event
updat pnh data suggest could competit soliri naiv soliri switch patient
today sell-off inferior respons soliri inadequ respond transfusion-depend patient miss
remain opportun conced unmet need highest popul see path forward soliri naiv
transfus depend patient lower pt narrow market
shorten fda review time vs standard review april pdufa date see potenti
rubraca earli approv potenti launch mainten given competitor zejula lynparza
previous receiv approv mainten ahead pdufa respect date zejula approv
march vs june pdufa lynparza approv aug vs sept pdufa view prioriti
review favor though complet unexpect given prior fda prioriti review competit agent zejula
lynparza respect ovarian cancer mainten nda
roch report clinic meaning bleed control hemlibra dose today roch announc top-lin data
trial hemlibra hemea patient dose schedul data line roch nov
abstract see bivv abstract takeaway note unexpect recal pk data outlin
abstract show hemlibra dose given sc half-lif day today report
roch confirm pk characterist translat clinic benefit bleed control result add
hemlibra disrupt potenti hemea long-term competit pressur eloct view data ad
conveni advantag hemlibra vs eloct regimen
tnbc recommend dose
updat data sabc highlight viabl dose compel efficaci manag safeti
see program larg upsid stock model probabl success shift focu
io combin
titl link note
nejm pub editori
net posit ahead present
takeaway look legit
rrnhl question remain
adcetri data accompani editori publish nejm link pub link editori came
away posit impress reinforc adcetri util hl given adcetri ad benefit across patient
subgroup view data support use adcetri across frontlin stage hl patient vs concern full
data present could indic higher risk patient benefit treatment anticip bear continu
focu numer differ modifi experiment vs control arm somewhat
increment vs though editori note two point see favor adcetri use trial use
stringent modifi includ use subsequ therapi case respons less
complet deauvil score safeti profil adcetri associ fewer treatabl
toxic evidenc treatment-rel death experiment arm due myelotox vs
control arm bleomycin-associ pulmonari toxic taken togeth editori see data
merit shift long-stand standard care avbd adcetri
anticip trade rel flat appear promis nhl cemiplimab question
remain initi cemiplimab show activ remain question vs competit
show favor risk/benefit profil despit toxic nhl cemiplimab mono combo dose
escal data show earli activ non-hodgkin lymphoma nhl hodgkin lymphoma hl though respons
rate seen exist standard care soc monotherapi data r/r nhl show meaning level
activ dose could becom competit exist car-t agent futur importantli initi safeti
find appear highli promis low case neurotox patient death boost
profil vs car-t especi earlier line therapi program remain upsid current valuat
alcanza mtcl run-in support
full result favor adcetri util stage hl support peak us sale estim
despit continu debat updat alcanza result support ctcl market opportun mtcl
data provid posit read-through outcom vs soc
takeaway idh continu
impress drive-pk data ad safeti
competit bivv eloct hemlibra hemea focu updat continu show
hemlibra disrupt potenti howev convers physician hemophilia kol dinner remain
construct eloct maintain market share specif physician note hemlibra like see broad use
inhibitor patient though physician appear reluct switch patient onto hemlibra effect factor
replac therapi without signific unmet need on-going bleed poor complianc potenti restart
factor replac therapi patient receiv hemlibra question monitor pre-treat procedur remain
key question physician check support bivv pipelin come poster beta-th start
natur histori data support unmet medic need cagd thromboembol te event due
hemolysi importantli occur independ patient anem statu
updat drive-pk data continu support pivot studi weekend present
updat result on-going drive-pk studi patient pkd pyruv kinas defici
continu show rapid durabl increas hb favor risk/benefit continu show mild aromatas
inhibit profil impact sex hormon though data appear modest men larg remain within
normal rang women
titl link note
compel
luspatercept pace-md data improv poc mf offset emerg competit beta-thalassemia updat
result pace-md studi show continu strong luspatercept hb improv md pt anemia
support convict luspatercept weekend updat pace-md data luspatercept md
patient anemia improv iwg hi-e well rbc-ti respons driven respons rate esa nave patient
increas hi-e increas ti non-r patient increas hi-e increas ti recal on-going
medalist studi enrol rs patient refractori esa base earlier observ
luspatercept efficaci popul howev command studi design enrol frontlin md patient
regardless rs statu base addit data collect pace-md studi present time
see updat data set strong proof luspatercept clinic benefit esa refractori patient patient
nave esa treatment thu bode well potenti posit outcom command studi
weekend key area focu within coverag includ broad adcetri util hl
bivv hemlibra competit eloct hemea inter-pati variabl fviii express level valrox
safety/efficaci
host dinner sunday even lymphoma kol top academ center overal relat
cover compani physician echo mani concern heard throughout weekend
complex deliv get reimburs car-t therapi commerci set continu believ
make initi uptak cellular therapi like gild yescarta gradual believ issu
insurmount continu see signific lt opportun field
gain limelight challeng confront
base exposur studi cohort
morn updat data valrox competitor hemea gene therapi present see
emerg favorit vs competit base efficacy/safeti profil well lead market
dose base best-cas exposur scenario today poster post earli
access postercast present postercast note dose base exposur studi
cohort high dose cohort studi saw breakthrough hemolysi normal ldh
patient view dose base exposur suggest could show improv vs soliri
on-going trial endpoint given soliri respons remain lumpi within time period could enabl
rapid sustain decreas normal ldh show benefit importantli poster also note
patient studi subsequ transfer dose paradigm ldh level
remain suppress view new disclosur import earli read-through dose efficaci
